During the past decade, Grayline Clinical Drug Trials conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 25 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 14 clinical trials were completed. i.e. 87.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Grayline Clinical Drug Trials" #1 sponsor was "Pfizer" with 8 trials, followed by "Naurex, Inc, an affiliate of Allergan plc" with 4 trials sponsored, "Shire" with 4 trials sponsored, "Sunovion" with 4 trials sponsored and "Biohaven Pharmaceuticals, Inc." with 4 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Grayline Clinical Drug Trials" #1 collaborator was "APCER Life Sciences" with 1 trials as a collaborator, "INC Research Limited" with 1 trials as a collaborator, "Institute for the Study of Aging (ISOA)" with 1 trials as a collaborator, "KCAS Bio" with 1 trials as a collaborator and "Neumora Therapeutics, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Grayline Clinical Drug Trials" are "Major Depressive Disorder" (10 trials), "Alzheimer's Disease" (9 trials), "Alzheimer Disease" (5 trials), "Depressive Disorder, Major" (5 trials) and "Osteoarthritis" (4 trials). Many other conditions were trialed in "Grayline Clinical Drug Trials" in a lesser frequency.

Most popular intervention types in "Grayline Clinical Drug Trials" are "Drug" (52 trials), "Other" (6 trials) and "Biological" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (25 trials), "placebo" (6 trials), "Rapastinel" (4 trials), "ATH-1017" (2 trials) and "BI 1358894" (2 trials). Other intervention names were less common.

The vast majority of trials in "Grayline Clinical Drug Trials" are 54 trials for "All" genders.

Currently, there are NaN active trials in "Grayline Clinical Drug Trials". undefined are not yet recruiting, 7 are recruiting, undefined are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 32 completed trials in Grayline Clinical Drug Trials, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Grayline Clinical Drug Trials, 0 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".